Alaa F. El-Daoushy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alaa F. El-Daoushy has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Adli AbdAllah Selim
Labeled Compounds Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt
1 shared publication - Basma M. Essa
Radioactive Isotopes and Generators Department, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt
1 shared publication - Charles Jeffrey Smith
Research Division, Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO 65201, USA
1 shared publication - Claudia G. Chambers
Department of Chemistry, University of Missouri, Columbia, MO 65201, USA
1 shared publication - Mohamed F. Nawar
Department of Chemistry, Biochemistry and Pharmaceutical Sciences, Faculty of Science, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland
1 shared publication - Mohamed M. Swidan
Labeled Compounds Department, Hot Labs and Waste Management Center, Egyptian Atomic Energy Authority, PO13759 Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects
Alpha therapy (TAT) relies on combining alpha-emitting radionuclides with specific cell-targeting vectors to deliver a high payload of cytotoxic radiation capable of destroying tumor tissues. TAT efficacy comes from the tissue selectivity of the targeting vector, the high linear energy transfer (LET) of the radionuclide, and the short range of alpha particles in tissues. Recent research studies have been directed to evaluate TAT on a preclinical and clinical scale, including evaluating damage to tumor tissues with minimal toxic radiation effects on surrounding healthy tissues. This review highlights the use of Actinium-225/Bismuth-213 radionuclides as promising candidates for TAT. Herein, we begin with a discussion on the production and supply of [225Ac]Ac/[213Bi]Bi followed by the formulation of [225Ac]Ac/[213Bi]Bi-radiopharmaceuticals using different radiolabeling techniques. Finally, we have summarized the preclinical and clinical evaluation of these potential radiotheranostic agents.
Open AccessActinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects
Alpha therapy (TAT) relies on combining alpha-emitting radionuclides with specific cell-targeting vectors to deliver a high payload of cytotoxic radiation capable of destroying tumor tissues. TAT efficacy comes from the tissue selectivity of the targeting vector, the high linear energy transfer (LET) of the radionuclide, and the short range of alpha particles in tissues. Recent research studies have been directed to evaluate TAT on a preclinical and clinical scale, including evaluating damage to tumor tissues with minimal toxic radiation effects on surrounding healthy tissues. This review highlights the use of Actinium-225/Bismuth-213 radionuclides as promising candidates for TAT. Herein, we begin with a discussion on the production and supply of [225Ac]Ac/[213Bi]Bi followed by the formulation of [225Ac]Ac/[213Bi]Bi-radiopharmaceuticals using different radiolabeling techniques. Finally, we have summarized the preclinical and clinical evaluation of these potential radiotheranostic agents.